Augmenting the Team , Aastrom Biosciences (ASTM)
ASTM announced the appointments of Sharon Watling, Pharm.D, as VP, Clinical and Regulatory, and Ronnda L. Bartel, Ph.D, VP, Chief Scientific Officer (formerly VP Technical Operations).
Dr. Watling will coordinate and manage all aspects of the continued clinical development of Aastrom products including the cardiac and vascular programs now positioned to advance to further late-stage development. Previously she worked in clinical development at Pfizer and at Warner-Lambert/Parke Davis prior to its acquisition by Pfizer. She was also site leader and senior director of clinical development at Metabasis and research and strategy development leader at Cognigen Corporation. Dr. Watling also has more than 10 years of experience as an intensive care unit clinical specialist and maintains adjunct faculty appointments at several academic institutions. In her new role, Dr. Bartel will be responsible for all company research, development, manufacturing and engineering operations. A 20-year veteran of the stem cell research and product development field, Dr. Bartel was involved in the development and approval of some of the first cell-based products approved by the FDA.
